INTRODUCTION
The MLL partial tandem duplication (MLL-PTD) produces an in-frame, elongated protein and occurs in approximately 8% of patients with cytogenetically normal (CN) acute myeloid leukemia (AML). 1 The MLL-PTD affects only one allele in CN-AML, and the second, wild-type (WT) MLL allele is silenced. 2 Unlike MLL chimeric fusion proteins arising from translocations involving 11q23, the MLL-PTD protein retains the C-terminal domains including the histone H3 lysine 4 methyltransferase activity. 3 In a murine knock-in model, the Mll-PTD acts as a gain-of-function allele giving rise to aberrations in skeletal development and conferring proliferation and selfrenewal advantages to hematopoietic stem/progenitor cells without causing frank leukemia. 4 The MLL-PTD was the first adverse prognostic molecular marker identified in CN-AML. 5, 6 In several subsequent studies, the presence of MLL-PTD was associated with a shorter remission duration, with most patients relapsing within one year. [7] [8] [9] [10] We report herein for the first time that younger adults with MLL-PTD (MLL-PTD+) treated on two recent frontline Cancer and Leukemia Group B (CALGB) protocols had a clinical outcome comparable to that of CN-AML patients without MLL-PTD (MLL-PTD-), and that a substantial percentage of MLL-PTD+ patients are disease-free beyond 2.5 years.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
PATIENTS AND METHODS
A combination of real time RT-PCR and nested RT-PCR/sequencing was used to detect MLL-PTD in pretreatment bone marrow (BM) or blood (PB) samples as previously described. 2 Table 1 ). The CR rate for MLL-PTD+ patients was similar to that reported in a German study 9 that administered idarubicin, cytarabine, and etoposide-based intensive doubleinduction therapy, and higher than CR rates observed in other studies (Table S1) . 7, 8, 17 Younger age (<60 years) and/or inclusion of etoposide may have contributed to the high CR rates in the CALGB and German studies.
With a median follow-up of 4.7 years, no significant differences in DFS (P=.55) or OS (P=.67)
between MLL-PTD+ and MLL-PTD-patients were observed ( Table 1 ). The estimated 3-year DFS and OS rates for MLL-PTD+ patients were, respectively, 41% and 50% compared with, respectively, 48% and 52% for MLL-PTD-patients (Table 1 ). Most striking was that 50% of MLL-PTD+ patients were alive at last follow-up and 9 of 22 (41%) were still in first CR (CR1), ranging from 2.2 to 7.7 years (Figure 1) . This is markedly different from data previously reported, where few adult MLL-PTD+ patients maintained a remission beyond 2 years (Table S1 ). In the Döhner et al. 9 study, CN-AML patients aged 16-60 years in CR1 were treated with a high-dose cytarabine and mitoxantrone-based (HAM) regimen for the first consolidation therapy, and yet 11 of 16 MLL-PTD+ patients relapsed within 2 years, and the 5 patients remaining in CR1 were censored with short follow-ups, from only a few months to about a year post remission. Two patients in the Döhner et al. 9 study, who achieved a second CR and received allogeneic transplantation, were alive with approximately three and a half to four years of follow-up. In the current study, 18 of 22 MLL- Although a considerable fraction of MLL-PTD+ patients were alive and relapse-free, the majority relapsed within the first 1.4 years of remission ( Figure 1 ). Thus, we analyzed the MLL-PTD+ group for pretreatment and/or molecular characteristics that might explain some of the differences in outcome in this subgroup. Relapsed patients had a higher percentage of BM blasts at diagnosis (median, 66% vs. 40.5%, P=.03) and more often were high BAALC expressers (P=.03) ( Table 1) .
Nine of 11 MLL-PTD+ patients with high BAALC relapsed whereas all three patients with low BAALC remain in remission ( Figure S1A ). While not statistically significant, the presence of other adverse molecular prognostic markers was also more frequent among relapsed MLL-PTD+ patients compared with MLL-PTD+ patients who remain in remission. Figure S1B-D) .
In conclusion, we have observed for the first time a relatively good outcome for MLL-PTD+ patients who achieved CR, with 41% of such patients remaining in first remission beyond 2.5 years.
This contrasts with previous studies reporting only a few patients who achieved long-lasting remissions. Besides the multitude of other potential factors, we postulate that treatment advances for younger adults may have contributed to the better outcome observed for the MLL-PTD+ patients reported in this study. Although these are encouraging findings, it is clear that the majority of MLL-PTD+ patients still relapse early. Our data suggest that the presence of additional, negative prognostic markers may be a contributing factor. Larger studies are necessary to confirm our results and to elucidate the underlying mechanisms of leukemogenesis, which could lead to the development of molecularly-targeted curative therapies. 
